ACRS (Aclaris Therapeutics) Moat Score: 4/10 (As of Jun. 30, 2026)


ACRS Aclaris Therapeutics Inc ACRS
38 GF Score
Price $5.04
GF Value $0.45
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Moat Score?

Aclaris Therapeutics ACRS +0.40% 38 Moat Score is 4 as of Jun. 30, 2026. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,401 Biotechnology companies, Aclaris Therapeutics ranks better than 88.79% on this metric.

Aclaris Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Aclaris Therapeutics has Narrow Moat: Aclaris has valuable intellectual property and patents in dermatology, providing some protection. However, it faces significant competition and lacks strong brand strength or customer loyalty, limiting its moat to a modest level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Aclaris Therapeutics might have Narrow Moat - Discernible but modest moat.

Aclaris Therapeutics  (NAS:ACRS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Aclaris Therapeutics Moat Score Related Terms

ACRS vs RLMD, GYRE, SGP: Moat Score Comparison

For the Biotechnology subindustry, Aclaris Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Moat Score falls into.


ACRS
38GF Score
Aclaris Therapeutics Inc ACRS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Aclaris Therapeutics (ACRS) has a Moat Score of 4 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Aclaris Therapeutics ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Aclaris Therapeutics' Moat Score too high?
Aclaris Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Aclaris Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Aclaris Therapeutics ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Moat Score compare to RLMD and GYRE?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #157 out of 1401 companies for Moat Score. This places Aclaris Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Aclaris Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aclaris Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclaris Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.04 — trading 1018.9% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Moat Score is 4 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.04 is trading 1018.9% above its estimated GF Value™ of $0.45. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Moat Score: 4
  • GF Value™: $0.45 vs. price of $5.04 (1018.9% above fair value)
  • GF Score™: 38/100 with 10 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1401)

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score

Get the complete analysis for ACRS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.04
Price
$0.45
GF Value